Category: Special Subpopulations

All Podcast Categories
S4-20.2 - Listening to Both Sides: Allied Health for Patient Empowerment

S4-20.2 – Listening to Both Sides: Allied Health for Patient Empowerment

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. In this conversation, Louise Campbell expands on the critical role of nurses as advocates with the unique ability to bridge the patient-physician gaps.

S4-20.1 - Who is going to be the Larry Kramer of NASH?

S4-20.1 – Who is going to be the Larry Kramer of NASH?

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This introductory conversation features an impactful statement from Donna on the gravity surrounding these milestone moments and why patient inputs should be held paramount.

S4-20 - Leveraging Patient Voice and Needs in the NASH Community

S4-20 – Leveraging Patient Voice and Needs in the NASH Community

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. Among other topics, the panelists comment on the recent draft report from ICER, the landscape of nomenclature consensus and, generally, how to absorb different perspectives into a common discussion while giving each the weight that they deserve.

S2-4 - What Can You Do Today to Prevent and Treat Fatty Liver Disease?

S2-4 – What Can You Do Today to Prevent and Treat Fatty Liver Disease?

Ken Cusi and Roger Green are joined by Diana Barb and Jay Shubrook in a discussion around effective therapies and strategies for fighting fatty liver disease that are available now. The group discusses frontline screening, medications, bariatric surgery, lifestyle management, practical insights and much more.

S4-19 - Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

S4-19 – Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session regarding the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.

S4-18.6 - From the Vault: Clinical Care Pathway: What Can Be Done Today?

S4-18.6 – From the Vault: Clinical Care Pathway: What Can Be Done Today?

Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation From the Vault answers the question “What Can Be Done Today?” in terms of screening and patient management without approved drugs.

S4-18.2 - Risk Stratification and Identification of NAFLD/NASH Patients in the Endocrinology Setting

S4-18.2 – Risk Stratification and Identification of NAFLD/NASH Patients in the Endocrinology Setting

In continuing conversation around clinical care pathways and the complex of metabolic diseases, SurfingNASH explores the key relationship and interplay between endocrinology and hepatology. This conversation features Cyrielle Caussy alongside Surfers Jörn Schattenberg, Louise Campbell and Roger Green discussing why endocrinology clinics are a critical setting for early identification of patients with NAFLD and NASH.

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.